The net profit of “Tchaikapharma High-Quality Medicines” AD for 2025 amounts to €3,075,294.29. The General Meeting of Shareholders, scheduled for June 24, will decide on its distribution.

The Board of Directors proposes that 10% of the net profit be allocated to a mandatory reserve (€307,529.43) and €13,764.86 to additional reserves.

The pharmaceutical company’s capital will increase by €2,754,000, which includes the remaining profit for 2025, amounting to €2,754,000.

Currently, the public company’s registered capital is €48,909,000.

Over the past twelve months, the company’s shares on the BSE have risen by over 10%, reaching a price of €9.55 per share. Tchaikapharma’s market capitalization amounts to €915,845,000.

The positive results are due to the expansion of the product portfolio with medications for the treatment of hypertension, antihyperlipidemic and antithrombotic agents, as well as medications for the treatment of gout, erectile dysfunction, and prostate hyperplasia. Contract manufacturing for Chaikapharma’s European partners is expanding, as is the production of dietary supplements for local partners under the Fanfari brand.